U.S. investors, Big Pharma race to find new medicines in China
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
The US relies on China for key medicines. They won’t be spared from tariffs
President Trump’s tariffs in China are in place and hitting all products imported from the country — including a number of pharmaceutical drugs that Americans rely upon. Chinese imports ...
FiercePharma7d
FDA slaps China-based API makers with separate warning letters outlining quality, testing shortfalls
A pair of Chinese manufacturers with active pharmaceutical ingredients that were previously shipped to the U.S. | The FDA ...
moneycontrol.com2d
Aurobindo Pharma to begin European supplies from China facility in April
Aurobindo Pharma will commence supplies to Europe from its China-based facility starting April 2025, Business Standard reported, citing the company's Chief Financial Officer Santhanam Subramanian.
freightwaves.com11d
Running on Ice: Chinese tariffs’ impact on the pharmaceutical supply chain
Impacts of tariffs on the pharmaceutical industry, cutting-edge container monitoring and the sheer number of chicken wings ...
FiercePharma4d
Fierce Pharma Asia—Astellas' investment focus; Mitsubishi Tanabe's buyout; Leqembi's 'expansion phase'
Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...